PMCB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
PharmaCyte Biotech Inc (PMCB) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The lack of positive financial performance, absence of strong trading signals, and no significant catalysts make it a hold at this time.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 71.09, and moving averages are converging, showing no clear trend. Key resistance levels are at 0.811 and 0.86, while support levels are at 0.65 and 0.601. The stock has a 60% chance to decline slightly (-0.44%) in the next day and a modest 1.5% gain in the next week.
No recent news or significant trading trends from hedge funds or insiders. The stock has a slight chance of a 1.5% gain in the next week based on historical patterns.
No recent news, congress trading data, or influential figure activity to drive sentiment. High implied volatility (615.
suggests uncertainty.
In Q3 2026, revenue remained at 0 with no growth. Net income dropped significantly (-48.90% YoY) to -$1,556,255, and EPS declined by -61.36% YoY to -0.17. Gross margin remains at 0 with no improvement.
No analyst rating or price target data available for PMCB.
